3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
2
Sponsor Class
OTHER
3
INDUSTRY
2
NIH
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
284
Carboplatin
216
Cisplatin
148
Paclitaxel
145
Gemcitabine
145
Bevacizumab
117
Pemetrexed
114
Docetaxel
103
Oxaliplatin
79
Cyclophosphamide
79
Dexamethasone
78
durvalumab
77
atezolizumab
77
Fluorouracil
77
Nivolumab
75
130-nm albumin-bound paclitaxel
71
Fulvestrant
68
Capecitabine
64
Injections
63
Cetuximab
63
Leucovorin
60
Rituximab
56
fludarabine
52
Lenalidomide
49
Prednisone
46
venetoclax
43
Irinotecan
43
Letrozole
40
enzalutamide
39
tislelizumab
38
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Biopsy, Large-Core Needle
×
90 days
×
Clear all
NCT03524430
2026-05-28
BREVITY
Rna Diagnostics Inc.
Phase NA
Active not recruiting
801 enrolled
NCT05520099
2026-04-29
ELEPHAS-02
Elephas
Active not recruiting
416 enrolled